

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445

Status	RECRUITING
Phase	Phase 4
Sponsor	Mayo Clinic
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (8)

- Postmenopausal women defined as 12 months of spontaneous amenorrhea, or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- Age 46-60 years old.
- BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² in the presence of adiposity-associated diseases (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- Presence of bothersome hot flashes (≥ 28 episodes per week and of sufficient severity to prompt patients to seek therapeutic interventions).
- Hot flashes must be present for > 30 days prior to study entry.

... and 3 more (see full listing online)

Exclusion (22)

- Current treatment with menopausal hormone therapy.
- Any current (past 4 weeks) or planned use of:
 - Estrogen-containing contraceptive methods or menopausal hormone therapy (oral, transdermal, high dose vaginal ring, injection, pellets).
 - Vaginal estrogen.
 - Androgens.

... and 17 more (see full listing online)

Locations (1 total)

Mayo Clinic in Florida, Jacksonville, Florida, United States